RA Capital Management BBNX Position
Exited5-Fund ConvergenceRA Capital Management exited their position in Beta Bionics, Inc. (BBNX) in Q3 2025, after holding the stock for 3 quarters.
The position was first reported in Q1 2025 and has been tracked across 3 quarterly 13F filings.
BBNX is a convergence signal: 5 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout in 167 days (Sep 30, 2026), making the timing of RA Capital's position particularly relevant.
Short interest stands at 17.8% of float with 6.2 days to cover, indicating significant bearish positioning against the stock.
About Beta Bionics, Inc.
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.
Full company profile →Short Interest
17.8%
6.2 days to cover
RA Capital Management BBNX Position History
Frequently Asked Questions
Does RA Capital Management own BBNX?
No. RA Capital Management exited their position in Beta Bionics, Inc. (BBNX) in Q3 2025. They previously held the stock for 3 quarters.
How many hedge funds own BBNX?
5 specialist biotech hedge funds currently hold BBNX, including Eventide Asset Management, RTW Investments, Driehaus Capital and 2 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did RA Capital Management first buy BBNX?
RA Capital Management's position in BBNX was first reported in Q1 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is RA Capital Management's BBNX position increasing or decreasing?
RA Capital Management completely exited their BBNX position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
BBNXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
RA Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →